retatrutide triple agonist obesity trial produces up to 30.3% weight loss in Phase 3 Weight loss with retatrutide as

Tirzepatide offers proven weight loss of 15-22% over 72 weeks and is available now by prescription, while Retatrutide shows potential for up to 24% weight loss in 48 weeks but remains in trials

The long-term improvements in obesity-related complications and cardiovascular risk factors after bariatric surgery have been well established, 1,2 including prediabetes and Type 2 diabetes mellitus

In summary, tirzepatide modulates metabolic and inflammatory pathways that may enhance airway stability in obesity-related OSAS (Figure 2)

Jay agrees, calling this a modest amount of weight loss

This gut hormone helps to promote weight loss in a few ways: Regulating blood sugar Slowing stomach emptying, which can help you stay full after you eat Reducing hunger cues and food noise in the brain, which may lead to consuming fewer calories Tirzepatide is a dual GLP-1 and GIP receptor agonist